Unilife Corp. has entered an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with an undisclosed, early-stage drug target. Unilife has also granted Novartis an option for exclusivity. Additional terms of the agreement were not disclosed.
Unilife will supply a customized delivery device, consisting of syringe, needle, tubing, controller and pump, for the administration of an investigational Novartis drug into a targeted organ in clinical trials.
Alan Shortall, chief executive officer of Unilife, said, "I am pleased with our success to date in being an effective collaborator with Novartis. This is another example of Unilife addressing the unmet needs of pharmaceutical companies to deliver advanced drugs in their pipelines. I am excited to supply Novartis with a differentiated game-changing device that provides alternative options for drug delivery."